Patents by Inventor Martin W. Rowbottom

Martin W. Rowbottom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 10053430
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 21, 2018
    Assignee: AMBIT BIOSCIENCES CORP.
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
    Publication number: 20180215727
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: July 18, 2016
    Publication date: August 2, 2018
    Inventors: Martin W. ROWBOTTOM, John Howard HUTCHINSON
  • LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
    Publication number: 20180186755
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: June 24, 2016
    Publication date: July 5, 2018
    Inventors: Martin W. ROWBOTTOM, John Howard HUTCHINSON
  • Heterocyclic compounds and methods of use thereof
    Patent number: 9938261
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: April 10, 2018
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
    Publication number: 20180057458
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 1, 2018
    Inventors: Martin W. ROWBOTTOM, John Howard HUTCHINSON, David LONERGAN
  • FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF
    Publication number: 20170369443
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Application
    Filed: September 5, 2017
    Publication date: December 28, 2017
    Inventors: Martin W. ROWBOTTOM, John Howard HUTCHINSON, Imelda CALDERON
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170298029
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny ABRAHAM, Shripad S. BHAGWAT, Brian T. CAMPBELL, Qi CHAO, Raffaella FARAONI, Mark W. HOLLADAY, Andiliy G. LAI, Martin W. ROWBOTTOM, Eduardo SETTI, Kelly G. SPRANKLE
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 9730937
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 15, 2017
    Assignee: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Biaryl acetamide compounds and methods of use thereof
    Patent number: 9725465
    Abstract: Biaryl acetamide compounds and compositions and their methods of use are provided for modulating the activity of class III receptor tyrosine kinases and for the treatment, prevention or amelioration of one or more symptoms of disease of disorder mediated by class III receptor tyrosine kinases.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: August 8, 2017
    Assignee: Ambit Biosciences Corporation
    Inventors: Mark W. Holladay, Gang Liu, Martin W. Rowbottom
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160362405
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: June 20, 2016
    Publication date: December 15, 2016
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • Heterocyclic compounds and methods of use thereof
    Patent number: 9452167
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: September 27, 2016
    Assignee: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160199375
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: March 18, 2016
    Publication date: July 14, 2016
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 9320739
    Abstract: Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: April 26, 2016
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150246042
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: January 26, 2015
    Publication date: September 3, 2015
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150196566
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: December 22, 2014
    Publication date: July 16, 2015
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 8969587
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: March 3, 2015
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Heterocyclic compounds and methods of use thereof
    Patent number: 8952058
    Abstract: Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFR? kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: February 10, 2015
    Assignee: Ambit Biosciences Corporation
    Inventors: Michael J. Hadd, Michael D. Hocker, Mark W. Holladay, Gang Liu, Martin W. Rowbottom, Shimin Xu
  • RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140045868
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 13, 2014
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, SHRIPAD S. BHAGWAT, BRIAN T. CAMPBELL, QI CHAO, RAFFAELLA FARAONI, MARK W. HOLLADAY, ANDILIY G. LAI, MARTIN W. ROWBOTTOM, EDUARDO SETTI, KELLY G. SPRANKLE
  • RAF kinase modulator compounds and methods of use thereof
    Patent number: 8618289
    Abstract: Compounds according to formula (I), compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. Formula (I): or a pharmaceutically acceptable salt, solvate, clathrate of hydrate thereof, wherein X is O or S(O)t; Ra is O or S.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: December 31, 2013
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • QUINOLINE AND ISOQUINOLINE DERIVATIVES FOR USE AS JAK MODULATORS
    Publication number: 20130296363
    Abstract: Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: November 7, 2013
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Raffaella Faraoni, Michael J. Hadd, Mark W. Holladay, Martin W. Rowbottom, Eduardo Setti